For instance, reduced m6A levels enhances the therapeutic efficacy of crizotinib, an ALK/ROS1/c-MET kinase inhibitor, in the treatment of non-small cell lung cancer (NSCLC) with high c-MET expression [42]. Here, MET is linked to non-small cell lung carcinoma.